BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Open|| Short (1M)
Edelweiss Recommends 'Buy' On Dr Lal PathLabs
According to Edelweiss, Dr Lal PathLabs has the best Return on Capital Employed (RoCE), asset turnover and working capital. The company's strategy is to expand its presence in pathology, diversify away from Delhi NCR and explore inorganic growth, the brokerage adds.